Literature DB >> 15093601

Development and evaluation of osmotically controlled oral drug delivery system of glipizide.

Rajan K Verma1, Sanjay Garg.   

Abstract

Extended release formulation of glipizide based on osmotic technology was developed and evaluated. The effect of different formulation variables, namely, level of solubility modifier in the core, membrane weight gain, and level of pore former in the membrane, were studied. Drug release was found to be affected by the level of solubility modifier in the core formulation. Glipizide release was inversely proportional to the membrane weight but directly related to the initial level of pore former (PVP) in the membrane. Burst strength of the exhausted shells increased with the weight gain of the membrane. On the other hand, burst strength decreased with an increase in the level of pore former in the membrane. Drug release from the developed formulations was independent of pH and agitational intensity, but dependent on the osmotic pressure of the release media. Results of SEM studies showed the formation of pores in the membrane from where the drug release occurred. The numbers of pores were directly proportional to the initial level of pore former in the membrane. The manufacturing procedure was found to be reproducible and formulations were stable after 3 months of accelerated stability studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093601     DOI: 10.1016/j.ejpb.2004.02.003

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  12 in total

1.  Floating osmotic drug delivery system of ranitidine hydrochloride: development and evaluation--a technical note.

Authors:  Pramod Kumar; Sanjay Singh; Brahmeshwar Mishra
Journal:  AAPS PharmSciTech       Date:  2008-03-18       Impact factor: 3.246

2.  Controlled porosity solubility modulated osmotic pump tablets of gliclazide.

Authors:  Arti Banerjee; P R P Verma; Subhash Gore
Journal:  AAPS PharmSciTech       Date:  2014-11-07       Impact factor: 3.246

3.  Development and optimization of micro/nanoporous osmotic pump tablets.

Authors:  Siracha Tuntikulwattana; Ampol Mitrevej; Teerakiat Kerdcharoen; Desmond B Williams; Nuttanan Sinchaipanid
Journal:  AAPS PharmSciTech       Date:  2010-05-25       Impact factor: 3.246

4.  Model drug as pore former for controlled release of water-soluble metoprolol succinate from ethylcellulose-coated pellets without lag phase: opportunities and challenges.

Authors:  Yuli Wang; Jingjing Dai; Xinyi Chang; Meiyan Yang; Ruifang Shen; Li Shan; Yong Qian; Chunsheng Gao
Journal:  AAPS PharmSciTech       Date:  2014-08-28       Impact factor: 3.246

5.  In vitro Evaluation of Novel Sustained Release Microspheres of Glipizide Prepared by the Emulsion Solvent Diffusion-Evaporation Method.

Authors:  P Phutane; S Shidhaye; V Lotlikar; A Ghule; S Sutar; V Kadam
Journal:  J Young Pharm       Date:  2010-01

6.  Development and evaluation of controlled porosity osmotic pump for nifedipine and metoprolol combination.

Authors:  Rajagopal Kumaravelrajan; Nallaperumal Narayanan; Venkatesan Suba
Journal:  Lipids Health Dis       Date:  2011-04-11       Impact factor: 3.876

7.  Development of floating chitosan-xanthan beads for oral controlled release of glipizide.

Authors:  Nilesh Kulkarni; Pravin Wakte; Jitendra Naik
Journal:  Int J Pharm Investig       Date:  2015 Apr-Jun

8.  Preparation, characterization and optimization of glipizide controlled release nanoparticles.

Authors:  J Emami; M S Shetab Boushehri; J Varshosaz
Journal:  Res Pharm Sci       Date:  2014 Sep-Oct

9.  Osmotic drug delivery system as a part of modified release dosage form.

Authors:  Rajesh A Keraliya; Chirag Patel; Pranav Patel; Vipul Keraliya; Tejal G Soni; Rajnikant C Patel; M M Patel
Journal:  ISRN Pharm       Date:  2012-07-17

10.  Formulation and evaluation of controlled porosity osmotic pump for oral delivery of ketorolac.

Authors:  Fatima Sanjeri Dasankoppa; Mahesh Ningangowdar; Hasanpasha Sholapur
Journal:  J Basic Clin Pharm       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.